496 related articles for article (PubMed ID: 20433684)
1. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
2. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.
Xu D; Li N; He Y; Timofeyev V; Lu L; Tsai HJ; Kim IH; Tuteja D; Mateo RK; Singapuri A; Davis BB; Low R; Hammock BD; Chiamvimonvat N
Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18733-8. PubMed ID: 17130447
[TBL] [Abstract][Full Text] [Related]
3. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.
Li L; Li N; Pang W; Zhang X; Hammock BD; Ai D; Zhu Y
PLoS One; 2014; 9(4):e94092. PubMed ID: 24718617
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
Li N; Liu JY; Timofeyev V; Qiu H; Hwang SH; Tuteja D; Lu L; Yang J; Mochida H; Low R; Hammock BD; Chiamvimonvat N
J Mol Cell Cardiol; 2009 Dec; 47(6):835-45. PubMed ID: 19716829
[TBL] [Abstract][Full Text] [Related]
7. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
Fang X
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
[TBL] [Abstract][Full Text] [Related]
8. Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Zhao C; Jiang X; Peng L; Zhang Y; Li H; Zhang Q; Wang Y; Yang F; Wu J; Wen Z; He Z; Shen J; Chen C; Wang DW
J Mol Cell Cardiol; 2023 Dec; 185():13-25. PubMed ID: 37871528
[TBL] [Abstract][Full Text] [Related]
9. Epoxylipids and soluble epoxide hydrolase in heart diseases.
Imig JD; Cervenka L; Neckar J
Biochem Pharmacol; 2022 Jan; 195():114866. PubMed ID: 34863976
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.
Islam O; Patil P; Goswami SK; Razdan R; Inamdar MN; Rizwan M; Mathew J; Inceoglu B; Stephen Lee KS; Hwang SH; Hammock BD
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28296232
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
[TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase activation by S-nitrosation contributes to cardiac ischemia-reperfusion injury.
Ding Y; Li Y; Zhang X; He J; Lu D; Fang X; Wang Y; Wang J; Zhang Y; Qiao X; Gan LM; Chen C; Zhu Y
J Mol Cell Cardiol; 2017 Sep; 110():70-79. PubMed ID: 28736260
[TBL] [Abstract][Full Text] [Related]
14. Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.
Morgan LA; Olzinski AR; Upson JJ; Zhao S; Wang T; Eisennagel SH; Hoang B; Tunstead JR; Marino JP; Willette RN; Jucker BM; Behm DJ
J Cardiovasc Pharmacol; 2013 Apr; 61(4):291-301. PubMed ID: 23232840
[TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase: a new target for cardioprotection.
Gross GJ; Nithipatikom K
Curr Opin Investig Drugs; 2009 Mar; 10(3):253-8. PubMed ID: 19333883
[TBL] [Abstract][Full Text] [Related]
16. ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW).
Papiashvili N; Gongadze N; Bakuridze A; Bakuridze K
Georgian Med News; 2021 Mar; (312):125-132. PubMed ID: 33964840
[TBL] [Abstract][Full Text] [Related]
17. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
Neckář J; Kopkan L; Husková Z; Kolář F; Papoušek F; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Malý J; Netuka I; Ošťádal B; Červenka L
Clin Sci (Lond); 2012 Jun; 122(11):513-25. PubMed ID: 22324471
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.
Chaudhary KR; Abukhashim M; Hwang SH; Hammock BD; Seubert JM
J Cardiovasc Pharmacol; 2010 Jan; 55(1):67-73. PubMed ID: 19834332
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.
Zhang W; Otsuka T; Sugo N; Ardeshiri A; Alhadid YK; Iliff JJ; DeBarber AE; Koop DR; Alkayed NJ
Stroke; 2008 Jul; 39(7):2073-8. PubMed ID: 18369166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
